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ABSTRACT. The interaction between the gut microbiota and their mammalian host is known to have 
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far-reaching consequences with respect to metabolism and health. We investigated the effects of eight 
days of oral antibiotic exposure (penicillin and streptomycin sulfate) on gut microbial composition and 
host metabolic phenotype in male Han-Wistar rats (n = 6) compared to matched controls. Early 
recolonization was assessed in a third group exposed to antibiotics for four days followed by four days 
recovery (n = 6). Fluorescence in-situ hybridization analysis of the intestinal contents collected at eight 
days showed a significant reduction in all bacterial groups measured (control, 1010.7 cells/g feces; 
antibiotic-treated, 108.4). Bacterial suppression reduced the excretion of mammalian-microbial urinary 
co-metabolites including hippurate, phenylpropionic acid, phenylacetylglycine and indoxyl-sulfate 
whereas taurine, glycine, citrate, 2-oxoglutarate, and fumarate excretion was elevated. Whilst total 
bacterial counts remained notably lower the recolonized animals (109.1 cells/g faeces) compared to the 
controls, two cage-dependent sub-groups emerged with Lactobacillus/Enterococcus probe counts 
dominant in one sub-group. This dichotomous profile manifested in the metabolic phenotypes with sub-
group differences in tricarboxylic acid cycle metabolites and indoxyl-sulfate excretion. Fecal short chain 
fatty acids were diminished in all treated animals. Antibiotic treatment induced a profound effect on the 
microbiome structure, which was reflected in the metabotype. Moreover, the recolonization process was 
sensitive to the microenvironment, which may impact on understanding downstream consequences of 
antibiotic consumption in human populations. 
KEYWORDS. Antibiotics, gut microbiota, recolonizing, bacteroidetes, firmicutes, metabolic profiling. 
BRIEFS. Covariation was observed between the microbiota and the urinary metabolic profile following 
antibiotic treatment in a rat model. Both the microbial recolonization patterns and the corresponding 
metabolic phenotype were strongly influenced by group housing and resulted in variations in host-
microbial co-metabolism. 
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INTRODUCTION 
 
The gut microbiota are now recognized as a significant factor in determining host health and with 
respect to conferring an extended metabolic capacity on the host. Substantial inter-individual 
variability occurs within the human gut microbiota and numerous host factors exert selective 
pressure upon the microbiome including host genome,1,2 diet,3 age,4 and drug therapy.5,6 In turn, 
microbial variation is known to influence host metabolic phenotype7 and the metabolic activity of the 
gut microbiota has been found to variously potentiate or ameliorate the toxicity of xenobiotics8-10 and to 
impact upon several diseases. The association of certain microbial compositions with host insulin 
resistance11 and obesity12 has led to a renewal in interest in the impact of the gut microbes on host 
health. Although host and microbial metabolism are known to be inextricably linked, little work has 
been conducted on elucidating specific molecular associations between microbes and their mammalian 
host.  
 
Exploration of direct mammalian-microbial interactions promises to achieve a better understanding of 
the underpinning role of the gut microbiota in mammalian health. The contribution of the microbiota 
towards inter-animal variation in disease etiology, drug metabolism and toxicity can be studied using 
models of reduced or simplified microbiota. Germ-free (GF) animals, with or without subsequent 
implantation of a reduced microbiota, have been widely used to investigate the relationship between 
host and microbial metabolism. These animals represent ‘knock-out’ models with lifelong gut microbial 
absence allowing covariation between phenotypic features or metabolic function and microbial 
composition to be studied. However, these ‘knock-out’ animals lack morphological and physiological 
characteristics associated with supporting an intestinal microbiota. GF animals have reduced body 
weight due to reduced calorific harvest from the diet, underdeveloped gut structure and absorptive 
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capacity, restricted maturation of the immune system, lower metabolic rate, smaller lungs, livers, and 
hearts and therefore reduced cardiac output. Arguably, this does not produce a meaningful comparison 
with ‘conventional’ animals and therefore a more appropriate model may be the antibiotic-treated (AB) 
animal, since it is more reflective of the morphology and physiology of a conventional (CV) animal 
whilst possessing a reduced microbiota. Suppression of the microbiota through the oral administration 
of antibiotics was first described by Van der Waaij and Sturm.13 Although the exact microbial 
composition of AB animals cannot be controlled, different antibiotics can be used to selectively target 
different groups of microbiota.  
 
Historically it has been difficult to evaluate the extent of microbial perturbation following antibiotic 
treatment because the majority (≥99%) of the microbiota could not be cultured. In this study 
fluorescence in-situ hybridization (FISH) analysis, a culture-independent, quantitative molecular-based 
technique, has been applied to assess the microbiota, allowing enumeration of several key bacterial 
groups. We combine this with high resolution 1H nuclear magnetic resonance (NMR) spectroscopic 
based profiling of urine and fecal water to provide an alternative surrogate means of ascertaining the 
influence of the gut microbiota on host metabolism. High resolution spectroscopy, in particular 1H NMR 
spectroscopy has been used to metabolically phenotype both GF14,15 and AB16 models of modulated 
microbiota and to provide a window into gut microbial composition and activity, where aromatic 
compounds such as hydroxyphenylpropionic acid (HPPA) and hippurate, produced either directly by the 
microbiota or through the concerted trans-genomic metabolism of the microbiome and host genome, can 
be profiled over time. Antibiotics such as vancomycin,16 enrofloxacin17 and antibiotic cocktails18 have 
been studied using this approach and were associated with modulation of multiple urinary and fecal 
metabolites such as amines and microbial metabolites of aromatic amino acids, which normalized after 
approximately three weeks (Supplementary Table S1).  
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A variety of antibiotics, including bacitracin, kanamycin, neomycin, streptomycin and penicillin, have 
been utilized either alone or in combination to effectively decontaminate the digestive tract. In the 
present study penicillin and streptomycin sulfate were selected for attenuation of the gut microbiota as 
they have complimentary bacteriocidal qualities. Penicillin G, a β-lactam antibiotic, is most effective 
against Gram-positive bacteria and is incompletely absorbed by the GIT (bioavailability about 15-30% 
on an empty stomach).19 Streptomycin is effective against Gram-negative bacteria and is poorly 
absorbed from the GIT and therefore should not enter systemic circulation preventing interference with 
host biochemistry. Here, we have used a parallel microbiological and metabonomic approach to 
characterize and integrate the microbial and metabolic profile of rats following both temporal 
microbiotal perturbation and also recolonization via the administration of antibiotics. 
 
EXPERIMENTAL SECTION 
 
Study Design. Male, Wistar derived AlpkHsdRccHan:WIST rats (n = 18) were obtained from the 
Rodent Breeding Unit at AstraZeneca, Alderley Park.  Animals were approximately ten weeks old, and 
housed three per cage. Food and water were available ad libitum and all animals were subjected to 12-
hour light, 12-hour dark artificial light cycle. Animals were acclimatized to these housing conditions 
prior to the start of the dosing regime. The rats were separated into three groups of six and antibiotic 
treatment was carried out following the protocol of Guo et al..20 The antibiotic solution, containing 4 
mg/ml Streptomycin and 2 mg/ml Penicillin G, was provided in the animals’ drinking water. The 
drinking water of the control (CN) group contained no antibiotics. The bacterially suppressed (SP) 
group was given free access to the antibiotic-water for eight days. Animals in the recolonizing (RC) 
group were given free access to the antibiotic-water for the first four days and were then switched to 
antibiotic-free water for the remaining four days of the study. All animals were euthanased by halothane 
inhalation on the eighth day of the study. 
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Sample collection. Urine sample collection was carried out overnight for 16 hours on days 3 to 4 and 
days 7 to 8 using metabolism cages. Fecal samples were taken on day 8 immediately prior to the 
animals being removed from the metabolism cages. Intestinal contents for FISH analysis were taken at 
necropsy.  
 
Enumeration of faecal microbial populations by fluorescence In situ hybridisation (FISH). Fecal 
samples were stored in an anaerobic cabinet (10% H2; 10% CO2; 80% N2) for no longer than 2 hours 
prior to processing. The enumeration of fecal microbial populations was carried out using fluorescently 
labelled 16S rRNA targeted oligonucleotide probes and fluorescence in situ hybridisation (FISH). 
Oligonucleotide probes (MWG-Biotech, Milton Keynes, UK) targeting the Atopobium group (5’-GGT 
CGG TCT CTC AAC CC), Bacteroides spp. (5’-CCA ATG TGG GGG ACC TT), Bifidobacterium spp. 
(5’-CATCCGGCATTACCACCC), Eubacterium rectale group (5’-GCTTCTTAGTCARGTACCG), 
Clostridium histolyticum group (5’-TTATGCGGTATTAATCTYCCTTT) and the 
lactobacilli/enterococci (5’-GGTATTAGCAYCTGTTTCCA) were used for enumeration of dominant 
members of the gut microbiota. The probes were labelled at the 5’ end with the fluorescent dye Cy3. For 
the enumeration of total cells, samples were stained with the nucleic acid stain 4’, 6’-diamino-2-
phenylindole (DAPI). Slides were enumerated using a Nikon microscope with an EPI-fluorescence 
attachment (Nikon UK, Kingston-upon-Thames, UK). Principal components analysis (PCA) was 
applied to the normalized FISH data to identify trends within the bacterial populations relating to 
antibiotic-induced bacterial suppression and subsequent recolonization. 
 
1H Nuclear Magnetic Resonance (NMR) spectroscopy. Urine samples were prepared by mixing 
400 μL of urine with 200 μL of phosphate buffer at pH 7.4 containing 10% D2O and 1 mM 3-
trimethylsilyl-1-[2,2,3,3-2H4] propionate (TSP) and then transferring the mixture to 5 mm outer 
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diameter NMR tube. For the fecal samples, 200-300 mg (one pellet) of stool was mixed with 1 mL of 
phosphate buffer at pH 7.4 containing 10% D2O, 3 mM sodium azide, and 1 mM TSP. The samples 
were sonicated for 30 min and then centrifuged at 14 000 g for 10 min to remove particulates before 
being transferred to a 5 mm outer diameter NMR tube. 
 
1H NMR spectra were acquired for each sample using a Bruker Avance 600 spectrometer operating at 
600.13 MHz. A standard one-dimensional NMR spectrum was acquired for each sample with water 
peak suppression using a standard pulse sequence (recycle delay (RD)-90°-t1-90°-tm-90°-acquire free 
induction decay (FID)). The RD was set at 2 s and the mixing time (tm) 100 ms. The 90° pulse length 
was approximately 12 μs and t1 was set to 3 μs. For each sample, 8 dummy scans were followed by 64 
scans and collected in 64 K data points using a spectral width of 20 ppm and an acquisition time per 
scan of 2.73 s. 
 
Data preprocessing and analysis. 1H NMR spectra were manually corrected for phase and baseline 
distortions and then referenced to the TSP resonance at δ 0.0. Spectra were digitized using an in-house 
MATLAB (version R2009b, The Mathworks, Inc.; Natwick, MA) script. To prevent baseline effects 
that arise from imperfect water saturation the region containing the water resonance was excised. An in-
house peak alignment algorithm21 was then performed on each spectrum in MATLAB to adjust for 
shifts in peak position due to small pH differences between samples and then each spectrum was 
normalized using a probabilistic quotient approach.22 For both the urine and fecal NMR spectra, 
principal components analysis (PCA) using unit variance scaling was applied in SIMCA (Umetrics, 
Umea). Orthogonal projection to latent structure discriminant analysis (OPLS-DA) models were 
constructed using unit variance scaling to aid the interpretation of the model and distinguish the 
metabolites that differed between the groups. Here, 1H NMR spectroscopic data were used as the 
descriptor matrix and class information (CN, SP, or RC) as the response variable. The contribution of 
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each variable (metabolite) to sample classification was visualized by back-scaling transformation, 
generating a correlation coefficient plot. These coefficient plots are colored according to the 
significance of correlation to ‘class’ (e.g. CN, SP, RC), with red indicating high significance and blue 
indicating low significance. The direction and degree of the signals relate to covariation of the 
metabolites with the classes in the model. For all models one orthogonal component was used to remove 
systematic variation unrelated to class. Predictive performance was assessed using the Q2Ŷ parameter. 
 
Since a decrease in the fecal short chain fatty acids was characteristic of the antibiotic-treated group, 
propionate, butyrate and acetate were quantified. An OPLS model was constructed to elucidate 
correlations between these individual fecal metabolites and components of the urinary metabolic profile. 
As diminished fecal short chain fatty acids were strongly characteristic of antibiotic administration, the 
relationship with the urinary metabolite profile was tested independently in the control (n=5) and 
treatment (n=6) groups, in order to discriminate specific relationships between fecal short chain fatty 
acids and urinary metabolites from correlations arising as a global response to antibiotic treatment. For 
propionate, the integral from the triplet at δ 1.04 in the fecal spectrum, arising from methyl group on the 
propionate molecule, formed the response variable (Y matrix) and was regressed against the whole 
urinary NMR spectrum (X matrix). The integrals from the singlet at δ 1.92 and triplet at δ 0.90 
corresponding to the methyl groups from acetate and butyrate respectively were correlated with the 
urinary metabolic profiles.  
 
RESULTS 
 
Clinical Observations and Histopathology. There were no adverse clinical observations recorded 
throughout the study. Water consumption remained constant in the CN group, however there was a 
pronounced increase in water intake in the SP and RC groups on days 2-3 and 5-7 compared to the CN 
 9
animals.  
 
FISH analysis of the bacterial profiles of intestinal contents collected at day eight following 
antibiotic dosing. Following eight days of antibiotic administration the average total number of 
bacterial cells (determined by the nucleic acid stain 4’, 6’-diamino-2-phenylindole (DAPI)) contained 
within the intestinal contents was reduced from 10.7 log10 cells/g in CN animals to 8.4 log10 cells/g SP 
animals. Those animals treated with antibiotics for four days and then allowed to recolonize for four 
days (RC) still supported substantially less bacteria (9.1 log10 cells/g of faeces) than the CN animals 
(Figure 1A). Individual probe counts were all significantly lower (p < 0.001) in the SP group compared 
to the CN group with the greatest change witnessed in counts for members of the Gram negative 
Bacteriodetes phylum covered by the Mib724 probe (CN = 10.35 log10 cells/g; SP = 7.58 log10 cells/g). 
Similar observations were noted in the RC animals except for the Lab158 counts (members of Gram 
positive Firmicutes phylum) where large intra-group variation occurred.  
 
Principal components analysis (PCA) performed on the FISH count data identified trends in the 
bacterial profiles between study animals. From the PCA scores plot (Figure 1B) it can be seen that CN 
animals were clearly discriminated from those groups treated with antibiotics and this was explained by 
higher counts of all probes in the CN group. The SP group clustered tightly, indicating greater 
homogeneity within the SP bacterial profiles than in the CN or RC groups, and was positioned 
marginally further away from CN animals than the RC animals. In the RC animals, two sub-groups 
emerged in the bacterial signatures (denoted RCα and RCβ). This sub-grouping appeared to correspond 
to the cage, with the three animals of the RCα sub-group being housed together and those of RCβ 
housed together. RCα had significantly higher Lab158 counts (Lab158 = 9.3 log10cells/g) than RCβ 
(Lab158 = 7.8 log10 cells/g, p = 0.003, determined by a two-tailed, unpaired Student’s t test). The PCA 
scores plot indicated that the bacterial signature of RCβ bore greater similarity to those animals treated 
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with antibiotics for eight days than RCα suggesting recolonization was more extensive in the RCα 
subgroup. This is corroborated by the significantly higher total average bacterial counts of RCα (9.5 
log10 cells/g feces) compared to RCβ (8.7 log10 cells/g feces, p < 0.001) animals. 
 
Gut microbial composition can be seen for each animal in Figure 1D where the relative abundance of 
each individual probe count can be observed. Bacteria enumerated by the Bac303 and Mib724 probes 
dominated the CN profile. Both of these probes measure bacteria belonging to the Bacteroidetes 
phylum. Probes specific to genera in the Firmicutes (Chis150, Erec482, Lab 158) and Actinobacteria 
(Bif164, Ato291) phyla were lower in abundance with both sets of probes measuring approximately 
five-fold lower than those of the Bacteroidetes phylum. 
 
Microbiotal composition was modulated in the SP group with a marked reduction in the proportion of 
Mib724 in relation to the total count and a notable rise in the proportion of Erec482, Ato291 and 
Bac303. Bacteria measured by the Bif164 probe were also noted to decrease in abundance. Collectively, 
probes measuring genera belonging to the Bacteroidetes phylum were lower in the overall profile of SP 
animals compared to CN animals although this was driven by the pronounced reduction in Mib724 
probe counts. In contrast, the proportion of probe counts enumerating genera of the Firmicutes and 
Actinobacteria phyla were observed to increase following eight days of antibiotic treatment, measuring 
approximately two-fold lower than the Bacteroidetes. 
 
The two sub-groups of the RC rats emerged with markedly different bacterial profiles. RCα was 
dominated by the Firmicutes phylum with an apparent bloom in the Gram-positive 
lactobacilli/enterococci (Lab158 probe). Diversity was narrow in these animals with Bif164 and 
Chis150 counts being low. RCβ was more similar in composition to the SP animals, with Bacteroidetes 
constituting the majority of the bacterial profile. As witnessed in the SP animals, the Bacteroidetes: 
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Firmicutes ratio was altered in the RCβ group with the abundance of the measured Firmicutes increased 
and Bacteroidetes decreased compared to the CN. Lab158 and Erec482 counts were higher 
proportionally in RCβ compared to the CN group. RCβ also contained a higher ratio of Actinobacteria 
with Ato291 and Bif164 constituting a greater amount of the overall profile compared to CN animals. 
 
Figure 1 
 
 
Effect of antibiotic dosing upon urine 1H NMR spectroscopic profiles (day eight). At day eight 
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the urinary metabolic profiles of SP and RC animals were noticeably different in composition to CN 
animals as determined by PCA (Figure 2A). These differences were more pronounced in the SP 
animals. Pair-wise comparisons of each group showed clear differentiation in the urinary metabolic 
profiles between all groups (Figure 2B-D). 
 
OPLS-DA coefficients plots were generated from the models of these pair-wise comparisons to aid 
interpretation, indicating the variables (1H NMR chemical shifts) responsible for the separation 
witnessed in the scores plots (Table 1). As expected, the model calculated from comparing CN and RC 
animals (Q2Ŷ = 0.87) was weaker than that comparing CN and SP animals (Q2 Ŷ = 0.91). SP animals 
were found to excrete higher amounts of glucose, the ketone body D-3 hydroxybutyrate, and the TCA 
cycle intermediates 2-oxoglutarate, citrate and fumarate than CN animals. The amino acids, taurine, 
glycine, and alanine, in addition to allantoin, creatine, creatinine, choline, phosphocholine, betaine, 
dimethylglycine, lactate, formate and N-acetyl-glycoprotein fragments were also excreted in greater 
amounts in the SP animals. Bacterial suppression reduced the amount of microbially-derived 
metabolites excreted including 3-hydroxyphenylpropionic acid (3-HPPA), 4-HPPA, hippurate, indoxyl 
sulfate and phenylacetylglycine (PAG); trimethylamine-N-oxide (TMAO) and acetate excretion was 
also lower in the SP animals at day eight. 
 
The urinary metabolic profiles of RC animals differed to those of CN animals (Figure 2C and Table 1) 
with higher concentrations of alanine, allantoin, creatine, creatinine, N-acetyl-glycoprotein and taurine 
observed. Metabolites involved in choline metabolism (choline, phosphocholine, betaine, 
dimethylglycine and glycine) were elevated in the urine of RC animals at day eight as were glucose, 
citrate, 2-oxoglutarate and D-3 hydroxybutyrate. After four days of recolonization urinary 
concentrations of 3-HPPA, 4-HPPA, hippurate, PAG, indoxyl sulfate and TMAO remained lower than 
in controls. The subgroups observed in bacterial profiles also emerged in the metabolic profiles of the 
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urine at day eight (Figure 2E). The RCα profile was closer in composition to the CN animals than RCβ, 
which correlated to the higher bacterial load in the RCα animals. The loadings plot from the PCA model 
revealed RCα animals excreted more 4-HPPA, PAG, indoxyl sulfate, acetate and less 2-oxoglutarate, D-
3 hydroxybutyrate, alanine, citrate, creatinine, glycine, lactate, N-acetyl-glycoprotein, and N-
methylnicotinamide when compared to the RCβ group. 
 
Differences were observed between the RC and SP urine at day eight although the separation between 
the two groups was less pronounced than comparisons to CN animals (Figure 2D). SP animals excreted 
greater amounts of betaine and surprisingly PAG. RC animals excreted higher amounts of 4-HPPA and 
indoxyl sulfate. The urine of subgroup RCβ was more similar in composition to the SP urine than RCα. 
 
Figure 2 
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1H NMR spectra of the urine collected from all study animals (day four). At day four both SP and 
RC animals had received antibiotics in their drinking water for the same period of time and were 
therefore at this point maintained under identical experimental conditions. An OPLS-DA model was 
built where the CN animals constituted one class (n = 6) and the SP and RC animals were combined to 
form the second class (n = 12). The cross-validated (Q2Ŷ = 0.8) predictive scores plot extracted from the 
OPLS-DA model (Figure 3B) show the urinary metabolic profiles of control and treated animals were 
clearly discriminated at day four and that all treated animals shared a similar metabolic profile. The 
corresponding OPLS-DA coefficients plot is shown in Figure 3A, explaining the metabolites 
responsible for the separation witnessed in Figure 3B. Antibiotic dosing was found to increase relative 
concentrations of the TCA cycle intermediates 2-oxoglutarate and citrate and, in addition, amounts of 
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creatinine, taurine, and N-acetyl-glycoprotein fragments were also increased. Decreased concentrations 
of 3-HPPA, 4-HPPA, PAG, hippurate, trimethylamine-N-oxide, and indoxyl sulfate (Table 2) were 
observed in the AB group. 
 
Figure 3 
 
 
Impact of antibiotic administration on the metabolic profiles of fecal extracts (day eight). At day 
eight the fecal metabolite profiles of SP and RC animals were markedly different from the CN group. 
This was confirmed by the construction of OPLS-DA models comparing CN with SP animals (Q2Ŷ = 
0.98) and CN with RC animals (Q2Ŷ = 0.98) (Figure 4, metabolic differences listed in Table 2). 
Interestingly, unlike the urinary profiles, SP and RC fecal samples were found to be similar in metabolic 
composition, despite the four days of recolonization in the RC group (as illustrated by the poor 
discriminatory model strength between the two classes, Q2Ŷ = -0.06). SP and RC animals were 
observed to excrete higher amounts of taurine, tryptophan, asparagine and choline, and noticeably 
higher amounts of oligosaccharides than the CN animals. The microbially-synthesized short chain fatty 
acids (SCFA), namely acetate, butyrate and propionate were found to be reduced in the SP and RC rats 
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along with alanine, lactate, methionine and succinate levels. Penicillamine, a major metabolite of 
penicillin, was measured in the feces of both SP and RC animals, with higher amounts observed in the 
SP animals. 
 
The composition of fecal SCFA was modulated by the antibiotic treatment in favor of butyrate and 
propionate (supplementary table S2). The CN animals excreted acetate:butyrate (1:0.21) and 
acetate:propionate (1:0.13) whilst the SP animals excreted acetate:butyrate (1:0.39) and 
acetate:propionate (1:0.35). Similar alterations were observed in the RC animals (acetate:butyrate 
(1:0.35); acetate:propionate (1:035)). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 
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Correlation of fecal SCFAs to urinary metabolites. To elucidate the relationship between microbial 
activity in the gastrointestinal tract and host endogenous metabolism, fecal levels of the SCFA, 
propionate, butyrate and acetate, were correlated to the urinary metabolic profiles of CN animals using 
OPLS (supplementary table S3). Metabolic connections were observed between the SCFA and urinary 
components. All fecal SCFA positively correlated with urinary formate, creatine, and taurine and 
negatively correlated with 2-oxoglutarate, citrate, malonate, malate, N-acetyl-glycoproteins and inosine. 
The strongest model was obtained when fecal butyrate was regressed against the urine profile (Q2Ŷ = 
0.90) with the model being additionally driven by positive correlations with acetate and negative 
correlations with creatinine and glycine. Fecal propionate (Q2Ŷ = 0.76) correlated strongly with 
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metabolites implicated in energy metabolism including negative correlations with fumarate. Hippurate, 
methylamine, phosphocholine and lactate were also negatively correlated with propionate whilst 4-
HPPA was positively associated (Figure 5). Fecal acetate (Q2Ŷ = 0.77) correlated positively with 
urinary acetate and negatively with fumarate, PAG, methylamine, phosphocholine, creatinine, glycine 
and lactate. 
 
Figure 5 
 
 
DISCUSSION 
 
Penicillin and Streptomycin shift microbiotal balance in favour of Firmicutes, modulate energy 
metabolism: After eight days of penicillin and streptomycin administration the bacterial counts of all 
the probes analyzed in the intestinal contents of the dosed rats were significantly reduced. 
Compositional makeup of the microbiota was modulated by antibiotic therapy, whereby the relative 
proportions of bacteria enumerated by the Erec482, Ato291, and Bac303 probes were increased in the 
overall profile and the proportion of those selected by the Mib724 probe were noticeably decreased. At 
the phylum level a reduction in the relative proportion of the Bacteroidetes was observed following 
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eight days of antibiotic treatment with a subsequent rise in the Firmicutes and Actinobacteria.  
 
Such changes are noteworthy due to increasing literature reports implicating such shifts in the 
etiology of obesity. Work by Ley et al.12,23 reported that the proportion of Bacteroidetes was lower in 
obese individuals in both mice and humans, whilst the proportion of Firmicutes was higher. 
Bacteroidetes abundance was independent of food intake but increased with weight loss on two types of 
low calorie diets. Enhanced capacity for energy harvest by the obese microbiota through the production 
of SCFA was proposed as the mechanism promoting weight gain.24 Schwiertz et al confirmed the 
association between SCFA metabolism and obesity but reported a decrease in the Firmicutes to 
Bacteroidetes ratio in overweight and obese adult humans.25 A further study found weight loss diets in 
obese subjects to significantly modulate gut microbial fingerprints but found no connection between 
Bacteroidetes and Firmicutes in human obesity.26 These findings suggest that the connection between 
the gut microbiota and obesity may be more intricate in nature than a simple phylum-level shift would 
account for but nevertheless implicates energy harvest from the diet as a potential underlying 
mechanism.  
 
Antibiotic consumption in the 20th century has been proposed as a factor in increased human obesity27 
with the gut microbiota suggested as a mechanism. Since the 1940s, antibiotics have been recognized to 
exert growth promoting effects by raising feed-conversion efficiency28 and were utilised in livestock 
farming to improve weight gain until 2006, when subtherapeutic antibiotic use in agriculture was 
banned in the EU. Since antibiotic supplements need to be taken orally to be effective in weight gain, 
community modulation of the gut microbiota must underlie these growth alterations. Moreover, weight 
gain does not occur in germ-free animals after oral administration of antibiotics.29 Modulation of the 
Firmicutes:Bacteroidetes balance observed in the current study supports the notion that antibiotics may 
elicit these growth effects through disruption of energy extraction metabolism due to either antibiotic 
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resistance in the Firmicutes or antibiotic sensitivity in the Bacteroidetes. Specifically, the Mib724 
population of Bacteroidetes appeared to be the most susceptible of the probes measured to the 
antibiotics.  
 
Consistent with altered intestinal ecology influencing energy extraction efficiency, the microbial 
fermentation products, SCFA and lactate, were notably reduced in the fecal water following antibiotic 
administration whilst the SCFA-precursors, oligosaccharides, were elevated. In alignment with bacterial 
compositional changes the relative proportions of butyrate and propionate to acetate were increased in 
the antibiotic-treated animals (supplementary Table S2). Modulations were also observed in host 
endogenous energy metabolism with increased urinary excretion of TCA cycle intermediates (citrate, 2-
oxoglutarate and fumarate), glucose, the ketone body D-3 hydroxybutyrate, and metabolites indirectly 
related to energy metabolism alanine, and lactate.  
 
The close relationship between microbial SCFA and host energy metabolism was demonstrated in the 
control animals where the fecal abundance of SCFA, in particular propionate, were observed to 
negatively correlate to several intermediates of the TCA cycle in the urine (citrate, 2-oxoglutarate, 
fumarate, malate, malonate). Taken together, these findings suggest that increased production of SCFA 
by the gut microbiota, and therefore increased bioavailability along the GIT, has a negative impact on 
the TCA cycle, thus reflecting a shift in energy strategy dependent upon the availability of these 
microbial products.  Whilst modulation of energy metabolism may be attributable to either reduction in 
bacterial activity or compositional shifts, these findings reinforce the connection between the microbiota 
and host energy metabolism. 
 
Endogenous and combinatorial metabolic modulation following microbial depletion: Covariation 
in the urinary metabolic signature and the bacterial profile demonstrate bacterial modulation had a 
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pronounced effect upon the co-metabolic phenotype of the host. Bacterial abundance, and therefore 
bacterial metabolic activity, was reduced by the penicillin/streptomycin regime. Additionally, variation 
witnessed in the microbial composition was statistically associated with variation in the microbiome 
with potential to influence different metabolic endpoints. A high degree of metabolic redundancy is 
encoded within the microbiome where common functional categories of genes and metabolic pathways 
are provided by several distinct bacterial species. Collectively, these contributions yield a ‘core 
microbiome’ with a combined core metabolic capacity, and which share similarity in function across 
unrelated healthy individuals.30 In this study antibiotic-induced microbial disruption was sufficient to 
perturb the host metabolic profile suggesting the core microbiome of these animals had been disrupted. 
 
Metabolites derived from concerted mammalian-microbial co-metabolism were reduced in the urine 
of SP animals following gut bacterial reduction. These compounds included 3-HPPA, 4-HPPA, PAG, 
hippurate and indoxyl-sulfate.  Hippurate is a well understood mammalian-microbial co-metabolite 
originating from bacterial action upon plant phenols to produce benzoate which becomes conjugated 
with glycine in the liver to produce hippurate. The aromatic species, 3-HPPA and 4-HPPA arise through 
the bacterial hydrolysis of dietary derived chlorogenic acid and further bacterial reduction of caffeic 
acid and a subset of microbiota have trytophanase activity which metabolizes tryptophan to indole and 
subsequently undergoes hepatic biotransformation to produce indoxyl-sulfate. Anaerobic bacterial 
metabolism of phenylalanine and phenols leads to the formation of phenylacetate, which can be 
conjugated with glycine in the liver to form PAG. 
 
Conversely, the loss of bacterial activity in the intestinal tract leads to an increase in metabolites 
typically degraded by such catabolism, improving their bioavailability, increasing the amount reaching 
circulation and consequently amount excreted. Increased excretion of taurine in the urine and feces of 
SP animals most likely relates to this reduced microbial action upon dietary taurine. High 
 22
concerntrations of urinary taurine is characteristic of germ-free and acclimatizing germ-free rodents.14,15 
Further evidence of microbially modulated taurine metabolism is the increase in tauro conjugated bile 
acids in various tissues (heart, liver, kidney) in germ-free rats.31 A similar trend towards an increase in 
the tauro-conjugated bile acid pool was noted following antibiotic treatment. Increased urinary excretion 
of creatine and creatinine may also arise from quelling of bacterial metabolism, with bacteria isolated in 
human feces possessing the metabolic capacity to degrade creatine and creatinine.32,33 
 
Endogenous choline metabolism was increased following suppression of bacterial activity, with 
choline, betaine, DMG and glycine increased in the urine of SP animals. Choline can be metabolized to 
glycine through a purely mammalian pathway or it can be converted in the gut via bacterial metabolism 
to trimethylamine (TMA) and subsequently oxidized in the liver to form TMAO.34 Increased urinary 
excretion of these metabolites and decreased TMAO excretion, in addition to increased choline in the 
feces, reflects an increased flux towards glycine synthesis in the host after microbially-mediated 
methylamine formation was removed. Although choline is required to synthesize phosphocholine and 
raised methylamine production has been implicated in non-alcoholic fatty liver disease, the elevated 
excretion of betaine, dimethylglycine and glycine observed in the current study indicates that choline 
bioavailability exceeds the necessary threshold for phosphocholine synthesis and is instead metabolized 
to glycine. 
 
Raised amounts of glycoproteins in the SP urine may indicate an inflammatory immune response to 
disrupted microbial ecology, where N-acetyl-glycoproteins are late biomarkers of inflammation and the 
acute-phase response.35 A fine balance exists between the mucosal immune system and the gut 
microbiota where a state of ‘controlled inflammation’ is maintained. However, fluctuations within this 
enteric community have the potential to provoke an inflammatory response to protect the host from 
translocating bacteria. There is also the possibility of alterations in barrier function. Indeed, certain 
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intestinal bacteria, such as the bifidobacteria, have been shown to directly regulate expression of tight 
junction proteins on mucosal epithelial cells, thus regulating intestinal permeability.36,37 Stimulation of 
this group of intestinal bacteria using specific dietary fibre supplements, e.g. the prebiotic oligofructose, 
has been shown to reduce chronic systemic inflammation associated with metabolic disease and weight 
gain.36,38 Another contributing factor to inflammation may be the reduction in SCFA, with research 
demonstrating that SCFA have a role in the prevention of mucosal inflammation.39 This is corroborated 
by the negative correlation observed between fecal SCFA and urinary N-acetyl-glycoproteins in the 
control animals.  
 
Antibiotic-derived metabolites were not detected in the urine but the major metabolite of penicillin (a 
penicillamine structure δ 1.46 (singlet), 1.57 (singlet), 3.63 (singlet)) was observed in the fecal water. 
Microbiotal profiles were highly consistent within each study group for both the CN and SP animals, 
and across the two cages that constituted each study group, which was also reflected in their metabolic 
signatures.  
 
Short-term recovery from antibiotic administration was evaluated to investigate the impact of early 
GIT recolonization processes on the microbial and metabolic profiles and interactions. 
 
Early bacterial recolonization is dynamic and influenced by housing: Intrinsic population 
dynamics in the early phases of recolonization influence bacterial establishment and composition. This 
may include: the presence of symbiotic bacteria and the emergence of cooperative food webs and 
promotional cross-feeding (mutualistic relationship) between species; competition for resources and 
mucosal binding sites; or the presence of inhibitory strains that would otherwise restrict proliferation via 
interference mechanisms such as the production of toxic metabolites and antimicrobial compounds. The 
presence of existing bacteria resistant to the antibiotic effects would also influence the re-establishment 
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of the microbiota. In addition, those enteric bacteria with a greater ability to adapt to or alter the local 
environment may have a competitive advantage over less fit organisms. Spatially, whether a species 
inhabits the mucosa or luminal environment may also contribute to growth advantage. Collectively these 
factors ensure a dynamic recolonization process.  
 
Following four days of bacterial recolonization, the abundance of the microbiota remained 
significantly lower in the RC animals than the CN animals. Abundance was higher than SP animals, 
although the RC animals received only four days of antibiotic-treatment in the first instance compared 
to eight days in the SP group. By observing the RC group information regarding the recolonizing 
properties of the specific bacterial groups can be obtained.  
 
The different subsets emerging in the microbiota of RC animals post cessation of the antibiotic 
treatment demonstrate the influence of the microenvironment, in this case animal caging, upon 
recolonization. This is of interest considering host genotype, age, diet, and water were the same, and 
that animals were housed in the same room yet cage assignment alone was sufficient to profoundly alter 
early recolonization. What is also striking is the homogeneity of the microbial profiles within cage-
sharing animals for all study groups, possibly a consequence of coprophagy, illustrating the influence of 
co-habitants upon the microbial profile. The variability in recolonization response observed in both the 
microbial and metabolic profiles has the potential to impact on the metabolism of drugs and other 
xenobiotics. The gut microbiota are recognized as an important variable in defining the metabolic fate of 
some xenobiotics in the host, thus subtle variations in tightly controlled animal studies can modulate 
microbial composition with potential to modulate metabolic outcomes of drugs.40,41 
 
In general, there was an increased proportion of Firmicutes in the recolonizing profiles suggesting that 
bacteria belonging to this phylum may be better early colonizers than those of the phylum Bacteroidetes, 
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or at least recover more quickly following cessation of antibiotic ingestion. The high proportion of 
Lab158 probe counts in the RCα subgroup may relate to a particular bacterial strain or species, not 
present in RCβ, with a growth advantage in the early stage of recolonization. Alternatively the 
phylotype of these dominant organisms may encode resistance to the antibiotic regime and would 
therefore not endure the same degree of attenuation following antibiotic-treatment as those comprising 
the Lab158 probe count in the RCβ animals. Bacteria belonging to this group, including the lactobacilli 
and enterococci have been shown to transfer antibiotic resistance genes readily within the gut and 
certain strains are resistant to penicillin.42-44 Given the similarity in urinary metabolic profiles between 
all RC animals at day four yet clear distinction between the two subgroups at day eight, the concept of 
competitive recolonization appears more feasible.  
 
The urinary metabolic profiles show some of the findings observed in the SP animals persisted in the 
RC animals but to a lesser extent indicating that four days of recolonization was insufficient to restore 
the microbiome to its pre-dose functional state. These deviations from CN animals included elevated 
concentrations of taurine, DMG, creatine, creatinine, allantoin, and reduced TMAO and the co-
metabolites, 3-HPPA, 4-HPPA, PAG, hippurate, and indoxyl sulfate. Whilst the urinary metabolic 
profiles of RC animals differed in composition to the SP animals at day eight, the fecal profiles were 
comparable, highlighting the greater sensitivity of the urinary profile to differences in microbial 
composition and abundance. 
 
Metabolic differences between the RCα and RCβ subgroups aligned with the observed variance in the 
microbial profiles. However, given the higher bacterial load in RCα, it is difficult to elucidate if the 
covariation in the metabotype and the gut microbiota was related to differences in the gut microbial 
composition (microbiomic variation) or gut microbial abundance (variation in metabolic capacity). The 
higher bacterial load of RCα was mirrored by greater excretion of the co-metabolites 4-HPPA, PAG, 
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and indoxyl-sulfate. Interestingly, RCα had a higher percentage of Firmicutes and excreted a higher 
amount of the SCFA acetate in the urine, whilst the animals of subgroup RCβ excreted greater amounts 
of metabolites implicated in energy metabolism (2-oxoglutarate, citrate, NMND, and D-3 
hydroxybutyrate). The RCβ group bore greater metabolic resemblance to SP animals than RCα, as did 
the microbial profile, further emphasizing the close correlation between microbiome and host 
metabotype. 
 
The variation observed in the microbial and metabolic profiles of the two subgroups may reflect 
either, different stages in a dynamic recolonization process that would eventually converge upon a 
common stable climax community (temporal variation) or relate to different recolonization trajectories 
that stabilize upon compositionally different microbiota. In the latter, the biotransformation potential 
encoded in the microbiome may vary or in keeping with the concept of a core microbiome, whilst 
compositional variation may occur, functional homogeneity would be achieved. Consistent with these 
observations, Dethlefsen and Relman45 demonstrated large inter-individual variability in the recovery of 
gut microbial composition of humans receiving ciprofloxacin and noted that in all cases the post-dose 
composition was distinct from initial state. However this was based on a low study size (n = 3). Whilst it 
has been shown in previous studies that a period of three weeks is required for the gut microbiome to 
stabilise15,16, in this study we were concerned primarily with establishing the suitability of this model for 
studying the effects of antibiotic treatment as an alternative to the use of germ-free animals. We were 
interested in the initial phase of the recovery process, rather than the long-term consequences of the 
treatment, which will be studied in more depth in future work now that the model has been validated for 
short-term studies. 
 
Antibiotic intake has been associated with a number of human diseases including Clostridium difficile 
associated diarrhoea or colitis,46 susceptibility to gastroenteritis and more chronic disorders including 
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autism.47 Niche construction theory, where organisms alter their local environment and that of others, to 
modulate the selection pressures exerted upon themselves and their descendants, extend the effects of 
historical contingencies, such as antibiotic insult.3 It is therefore plausible that antibiotic dosing may be 
re-organizing the gut microbiota permanently, and in an uncontrollable manner and that the effects of 
this re-alignment would persist until further perturbations take place.  
 
CONCLUSIONS 
 
Antibiotic-treatment exerted a profound effect upon the gut microbiota of rats and subsequently the 
co-metabolic phenotype of the host. Such modulation was not exclusive to mammalian-microbial co-
metabolic pathways but also appeared to impact on endogenous host metabolism. These findings 
suggest the core microbiome was altered by the administration of antibiotics and is of interest given the 
multidimensional recolonization that can occur once antibiotic treatment ceases and reflects both local 
host and microbiota specific parameters. Restoration of the microbiome and it’s influence on host 
metabolism appears to have been largely ‘uncontrolled’ and in the present study we are unable to 
ascertain whether the microbiome would return to the pre-dose state and thus recover to the pre-dose 
metabolic phenotype. However, the dramatic differences in both the metabolic phenotype and the 
microbiome witnessed in this study raise interesting questions regarding the subsequent metabolic state 
of host after antibiotic intervention.  
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Supplementary table S1: Metabolic perturbations induced by various antibiotic regimes 
Study Sample Increased following 
antibiotic 
Decreased following 
antibiotic 
Yap et al.16 
Oral vancomycin 
in mice 
 
Urine α-ketoisovalerate, butyrate, creatine, 
creatinine, guanidoacetic acid, N-acetyl 
glycoprotein, glycine 
hippurate, PAG, taurine, TMA, TMAO  
Feces choline, oligosaccharides 5-aminovalerate, acetate, alanine, 
arginine, asparagine, aspartate, butyrate, 
glutamate, glycine, isoleucine, lactate, 
leucine, lysine, methionine, 
phenylalanine, propionate, taurine, 
tyrosine, uracil, valine 
Romick-
Rosendale et 
al.17 
Oral 
enrofloxacin in 
mice 
Urine creatine, creatinine, N-
isovalerylglycine, tartrate, TMA 
acetate, allantoin, taurine, TMAO, urea 
Feces Urea alanine, butyrate, isoleucine, leucine, 
propionate, threonine, valine 
Williams et al.18 
Oral neomycin 
sulfate, 
tetracycline 
hydrochloride, 
bacitracin in rats 
Urine  hippurate, 3-HPPA 
 
Supplementary table S2: Fecal short chain fatty acid (SCFA) ratios across the means of the study groups 
relative to acetate 
 Acetate Butyrate Propionate 
Control 1 0.21 ± 0.06 0.13 ± 0.06 
Suppressed 1 0.35 ± 0.02 0.35 ± 0.03 
Recolonizing 1 0.39 ± 0.03  0.34 ± 0.02  
RCα 1 0.38 ± 0.02 0.34 ± 0.01 
RCβ 1 0.39 ± 0.03 0.35 + 0.03 
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Supplementary table S3: Correlation coefficients extracted from OPLS models regressing individual 
fecal SCFA (acetate, butyrate, propionate) against urinary metabolites 
Urinary metabolite Acetate 
Q2Y = 
0.77 
Butyrate 
Q2Y = 
0.90 
Propionate
Q2Y = 
0.76 
Acetate 0.92 0.93 0.44 
2-oxoglutarate -0.59 -0.59 -0.71 
Citrate -0.65 -0.84 -0.92 
Fumarate -0.56 -0.48 -0.73 
Malonate -0.86 -0.81 -0.81 
Malate -0.59 -0.77 -0.8 
4-
hydroxyphenylpropionic 
acid 
-0.4 -0.27 0.7 
Phenylacetylglycine -0.57 -0.44 0.47 
Hippurate -0.24 -0.04 -0.72 
Formate 0.98 0.98 0.59 
N-acetyl-glycoprotein -0.9 -0.81 -0.52 
Methylamine -0.64 -0.22 -0.61 
Phosphocholine -0.57 -0.46 -0.89 
Creatine 0.62 0.81 0.97 
Creatinine -0.72 -0.73 0.07 
Taurine 0.98 0.93 0.9 
Glycine -0.85 -0.72 -0.34 
Lactate -0.68 -0.32 -0.79 
Inosine -0.98 -0.99 -0.53 
 
FIGURE CAPTIONS.  
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Figure 1: Microbial profiling analysis of the intestinal contents collected at day eight from all study 
animals. A) Total and target bacterial populations in the intestinal contents at day eight. Values are 
mean ± standard error of the mean and expressed as Log10 cells/g faeces as determined by FISH. B) 
PCA scores plot constructed from the FISH data comparing control, recolonizing and suppressed 
animals. Circled are the two sub-groups that emerge in the recolonizing group (RCα and RCβ) (R2 = 
0.97). C) Microbiotal composition at the phylum level. D) Impact of antibiotic-induced suppression and 
subsequent recolonization on the composition of the gut microbiota. Values represent the total probe 
count for the individual bacterial probes for control, recolonizing sub-groups RCα and RCβ and 
suppressed animals. 
 
Figure 2: Principal components analysis (PCA) of the urinary metabolic profiles of all study animals at 
day eight. PCA scores plot comparing the urinary metabolic profiles at day eight from A) control, 
recolonizing and suppressed animals (R2 = 0.50); B) control and suppressed (R2 = 0.45); C) control and 
recolonizing (R2 = 0.47); D) recolonizing and suppressed (R2 = 0.44); and E) the two subgroups of the 
recolonizing animals (RCα and RCβ). 
 
Figure 3: Orthogonal projection to latent structures-discriminant analysis (OPLS-DA) of urine collected 
from all study animals at day four. A) Predictive scores plot from the OPLS-DA model comparing 
control animals (black) with animals treated with antibiotics (blue) at day four. B) Coefficient plot 
extracted from the OPLS-DA model constructed from the urinary 1H NMR profiles at day four 
discriminating between the control and antibiotic-treated animals (recolonizing and suppressed). 3-
HPPA, 3-hydroxyphenyl propionic acid; 4-HPPA, 4-hydroxyphenylpropionic acid; DMG, 
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dimethylglycine; PAG, phenylacetylglycine; TMAO, trimethylamine-N-oxide. 
 
Figure 4: Orthogonal projection to latent structures-discriminant analysis (OPLS-DA) of feces collected 
from all study animals at day eight. OPLS-DA coefficient and predictive scores plots from the 1H NMR 
profiles of fecal water at day eight discriminating between control and suppressed (A and B Q2Ŷ = 0.98) 
and between control and recolonizing rats (C and D Q2Ŷ = 0.98). 
 
Figure 5: Metabolic correlations between fecal propionate and urinary metabolites determined by 
OPLS. Coefficient plot of the urinary metabolites from the control animals that correlated with fecal 
propionate signal (Q2Ŷ = 0.84). 
 
TABLES.  
Table 1: Urinary metabolite differences identified at day eight between control (CN), recolonizing (RC) 
and suppressed (SP) animals by OPLS-DA. Values are the correlation coefficient derived from the 
OPLS-DA model.  
Metabolite SP vs. CN 
Q2Ŷ = 0.91 
RC vs. CN 
Q2Ŷ = 0.87 
SP vs. RC 
Q2Ŷ = 0.51 
Microbially-derived 
3-HPPA† -0.64 -0.67 - 
4-HPPA -0.86 -0.64 -0.59 
Hippurate† -0.80 -0.80 - 
Indoxyl sulfate -0.94 -0.72 -0.66 
PAG† -0.81 -0.82 +0.71 
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Energy Metabolism 
2-oxoglutarate +0.53 +0.48 - 
Citrate +0.54 +0.53 - 
Fumarate† +0.47 - - 
Glucose +0.65 +0.67 - 
D-3-
hydroxybutyrate 
+0.47 +0.47 - 
Amino Acids 
Alanine +0.49 +0.75 - 
Taurine +0.75 +0.62 - 
Choline Metabolism 
Betaine +0.74 +0.49 +0.55 
Choline +0.75 +0.50 - 
DMG +0.57 +0.64 - 
Glycine† +0.64 +0.67 - 
Other 
Creatine† +0.80 +0.62 - 
Creatinine† +0.75 +0.74 - 
Formate +0.57 - - 
Acetate† -0.55 - - 
Lactate +0.48 - - 
N-acetyl-
glycoprotein† 
+0.84 +0.73 - 
Allantoin +0.82 +0.62 - 
TMAO† -0.74 -0.77 - 
Phosphocholine +0.84 +0.64 - 
+, relatively higher in the treatment group (SP or RC); -, relatively lower in the treatment group with 
respect to the control group. † observed after administration of vancomycin, enrofloxacin or an antibiotic 
cocktail in mice and rats.16-18 3-HPPA, 3-hydroxyphenylpropionic acid; 4-HPPA, 4-
hydroxyphenylpropionic acid; DMG, dimethylglycine; PAG, phenylacetylglycine; TMAO, 
trimethylamine-N-oxide. 
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Table 2: Metabolites significantly different in the feces following penicillin/streptomycin 
administration determined by OPLS-DA. Values are the correlation coefficient derived from the OPLS-
DA model.  
Metabolite SP vs. CN 
(Q2Ŷ = 
0.97) 
RC vs. CN 
(Q2Ŷ = 0.95) 
Antibiotic-related metabolites 
Penicillamine-
related 
+0.91 +0.81 
Short chain fatty acids (SCFA) 
Acetate† -0.91 -0.90 
n-butyrate† -0.71 -0.71 
Propionate† -0.92 -0.92 
Amino acids 
Alanine† -0.86 -0.89 
Taurine +0.84 +0.75 
Tryptophan +0.92 +0.92 
Asparagine +0.88 +0.73 
Methionine† -0.86 -0.93 
Other 
Oligosaccharides† +0.99 +0.99 
Choline† +0.87 +0.84 
Succinate -0.83 -0.85 
Lactate† -0.90 -0.92 
+, relatively higher in the treatment group (SP or RC); -, relatively lower in the treatment group with 
respect to the control group. † observed after administration of vancomycin, enrofloxacin or an antibiotic 
cocktail in mice and rats.16,17 
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